ezrin和E-cadherin在非小细胞肺癌中的表达及意义

背景与目的 有研究表明埃兹蛋白(ezrin)可与上皮钙黏素(E-cadherin)相互作用,参与肿瘤细胞的转移过程.本研究的目的是利用组织芯片技术探讨ezrin和E-cadherin在非小细胞肺癌(NSCLC)组织和淋巴结转移灶中的表达及其意义.方法 应用免疫组织化学LSAB法检测25例良性病变肺组织、287例NSCLC原发灶及120例淋巴结转移灶中ezrin和E-cadherin蛋白的表达.结果 NSCLC原发灶及淋巴结转移灶中ezrin过度表达率分别为57.8%(166/287)和83.3%(100/120),E-cadherin异常表达率分别为82.6%(237/287)和98.3%(118/120),差异均有统计学意义(P=0.000).ezrin过度表达率与病理分级(P=0.005)、转移(P=0.032)有密切关系.E-cadherin异常表达率与病理分级(P=0.024)、转移(P=0.015)、TNM分期(P=0.037)有密切关系.ezrin与E-cadherin表达呈负相关(P=0.029).COX多因素分析显示病理分级、转移、TNM分期、ezrin表达和E-cadherin表达是影响肺癌患者预后的危险因素(P＜0.05).结论 ezrin和E-cadherin可能与肺癌的转移有关;二者有可能作为NSCLC患者临床预后判断的指标.

Expression and their significance of ezrin and E-cadherin in non-small cell lung cancer

Background and objective It has been proven that ezrin protein may interact with E-cadherin protein and take part in metastasis of tumors. The aim of this study is to detect the expression of ezrin and E-cadherin and their significance in non-small cell lung cancer (NSCLC) with tissue microarray technique. Methods Ezrin and E-cadherin proteins were detected in 25 cases of benign pulmonary tissues, 287 cases of NSCLC tissues and 120 cases of metastatic lymph nodes by LSAB method of immunohistochemical staining. All patients were followed up. Results The overexpression rate of ezrin in primary NSCLC tissues and metastatic lymph nodes was 57.8% and 83.3% respectively (P=0.000). The abnormal expression rate of E-cadherin in primary NSCLC tissues and metastatic lymph nodes was 82.6% and 98.3% respectively (P=0.000). The overexpression rate of ezrin was significantly related to grading (P=0.005) and metastasis (P=0.032). The abnormal expression rate of E-cadherin was closely related to grading (P=0.024), metastasis (P=0.015) and TNM stages (P=0.037). There was a negative correlation between expression of ezrin and E-cadherin (P=0.029). Grading, metastasis of NSCLC, TNM stages, overexpression of ezrin and abnormal expression of E-cadherin were independent prognostic factors of NSCLC (P<0.05). Conclusion Overexpression of ezrin and abnormal expression of E-cadherin may promote tumor metastasis. Ezrin and E-cadherin may be useful prognostic markers for patients with advanced NSCLC.